Do I Qualify?
Amro Albanna's avatarPerson

Amro Albanna


San Francisco, CA

Member Since November 2023


Venture Capital
Public Companies


I am an innovation entrepreneur with 25 years of experience launching and growing companies around promising technologies. I co-founded Aditxt in 2017 with a vision of creating a publicly owned innovation company to advance and commercialize some of the most promising biotechnologies developed by leading research institutions. Aditxt went public on NASDAQ through an IPO in June 2020 enabling it to engage thousands of stakeholders globally in its mission. Aditxt is currently in the process of developing breakthrough innovations designed to monitor and reprogram the immune system with a goal of addressing organ rejection, autoimmune diseases, and allergies. Prior to Aditxt, I launched multiple startups to develop and commercialize innovations in varying fields including healthtech, nanotechnology, entomology, 3-D spatial tracking and pattern recognition, GPS and telecommunications, and ecommerce. I have exited ventures via M&A and taken others public on the American Stock Exchange, NASDAQ, OTC, and Frankfurt Stock Exchange.

Published content

To catalyze health innovation, it’s time for a fundamental shift


It's time for a systemic change in how we approach health innovation—for the benefit of all.

Company details


Company bio

A biotech company with a mission to accelerate humanity’s transition to the "Age of Immunity", we are the business busily decoding the human immune system. We are a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. Our immune reprogramming technology called Apoptotic DNA Immunotherapy™ (ADI™) is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technology called Aditxtscore™ is designed to provide a personalized comprehensive profile of the immune system.



Area of focus

Immune reprogramming
Immune monitoring

Company size

51 - 200